SB-743921
- Generic Name
- SB-743921
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33ClN2O3
- CAS Number
- 618430-39-0
- Unique Ingredient Identifier
- 24DSZ1VN92
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and lymphoma (non-hodgkin's).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 68
- Registration Number
- NCT00343564
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Caner Center, New York, New York, United States
🇺🇸Cornell University Medical Center, New York, New York, United States
SB-743921 In Patients With Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00136513
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath